Viridian Therapeutics, Inc.\DE (VRDN) Retained Earnings (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Retained Earnings of $1.9 billion for Q1 2026, up 279.8% year-over-year from $512.6 million in Q1 2025, and up 1.02% quarter-over-quarter from $1.9 billion in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Retained Earnings (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Retained Earnings history runs 14 years deep, the most recent figure standing at $1.9 billion for Q1 2026.
- In Q1 2026, Retained Earnings rose 279.8% year-over-year to $1.9 billion; the TTM figure through Mar 2026 stood at $1.9 billion (up 279.8% YoY), while the FY2025 annual figure was $1.9 billion, up 19271140.0% from the prior year.
- Retained Earnings for Q1 2026 stood at $1.9 billion, up from $1.9 billion in the prior quarter.
- The five-year high for Retained Earnings was $1.9 billion in Q1 2026, with the low at -$1.2 billion in Q3 2025.
- The 5-year median for Retained Earnings is -$442.4 million (2022), against an average of -$122.1 million.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings sank 310838.85% in 2022, then surged 19271140.0% in 2025.
- Viridian Therapeutics, Inc.\DE's Retained Earnings stood at -$488.2 million in 2022, then jumped by 100.07% to $338000.0 in 2023, then sank by 102.96% to -$10000.0 in 2024, then soared by 19271140.0% to $1.9 billion in 2025, then grew by 1.02% to $1.9 billion in 2026.
- Business Quant data shows VRDN's Retained Earnings at $1.9 billion in Q1 2026, $1.9 billion in Q4 2025, and -$1.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 2.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.13 Bn |
| Mar 31, 2026 | 1.95 Bn |
| Dec 31, 2025 | 1.93 Bn |
| Sep 30, 2025 | -1.22 Bn |
| Jun 30, 2025 | -1.18 Bn |
| Mar 31, 2025 | -1.08 Bn |
| Dec 31, 2024 | -10,000.00 |
| Sep 30, 2024 | 932,000.00 |
| Jun 30, 2024 | -839.44 Mn |
| Mar 31, 2024 | -774.50 Mn |
| Dec 31, 2023 | 338,000.00 |
| Sep 30, 2023 | 807.34 Mn |
| Jun 30, 2023 | -611.40 Mn |
| Mar 31, 2023 | -556.30 Mn |
| Dec 31, 2022 | -488.17 Mn |
| Sep 30, 2022 | -442.40 Mn |
| Jun 30, 2022 | -1.08 Mn |
| Mar 31, 2022 | 439.19 Mn |
| Dec 31, 2021 | -157,000.00 |
| Sep 30, 2021 | -329.35 Mn |